Developer docs
API playgroundTry for free, no card

Search company profiles

BioVenture

Full company profile

uuid00007e7

Namestring
BioVenture
Legal namestring
苏州工业园区元生创业投资管理有限公司
Company typeenum
Private
Founded yearint
2013
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSuzhou, China
HQ citystring
Suzhou
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, biotech investment, medical device investing, early-stage healthcare funding, growth-stage equity investment
Industry1 code
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code1 code
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

Annual management fees based on committed capital under management

bioventure.com.cn
2Carried Interest
TypeTransaction Fee
Description

Performance-based carried interest from successful portfolio exits and IPOs. 19 portfolio companies have listed on HKEX, STAR Board, and other exchanges.

bioventure.com.cn
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1VC fund management and performance fees
ModelOtherBilling cadenceAnnual
Notes

Fund management fees typically 2% of committed capital; carried interest typically 20% of profits above hurdle rate

bioventure.com.cn
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioVenture (元生创投) is a China-based venture capital firm that manages RMB and USD investment funds focused exclusively on early and growth-stage healthcare companies. It deploys capital across four areas—new drug R&D, medical devices, IVD and precision medicine, and healthcare services—and supplements investment with hands-on post-investment management and value-added services through the BioBAY ecosystem.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 19 portfolio companies successfully listed on exchanges (HKEX, STAR Board, etc.)
+1 more record
Product overview1 text field

BioVenture (元生创投) is a healthcare-focused venture capital firm offering investment fund management services. The firm operates multiple investment funds including a RMB fund (新建元生物产业基金) and a USD Fund II, targeting early and growth-stage healthcare companies across biotech, medical devices, IVD, and healthcare services. The firm provides capital deployment, post-investment management, and value-added services to portfolio companies through its network and platform resources.

Product and service2 records
1新建元生物产业基金 (Xinjianyuan Bio-Industry Fund)
CategoryInvestment Fund
Description

BioVenture's first RMB fund focused on early and growth-stage life sciences investments, covering new drug R&D, medical devices, IVD, and healthcare services. The fund has a 7-year term and invests across the firm's four healthcare verticals.

2YuanBio USD Fund II
CategoryInvestment Fund
Description

BioVenture's second USD-denominated fund investing in overseas healthcare innovation companies. Used to participate in cross-border rounds such as the Series A of BestView Laser in 2022.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading China VC with a dedicated healthcare practice spanning new drug R&D and medical devices. Comparable in stage focus (early/growth), sector, and Chinese institutional LP base.

TypeBroad incumbent
Description

Major cross-stage China VC with healthcare exposure across biotech and devices. Competes for healthcare deal flow but as part of a broader technology and consumer mandate.

3Legend Capital (君联资本)
TypeDirect peer
Description

Large China VC/PE firm with a substantial healthcare practice, comparable in stage and sector focus. Competes for the same growth-stage healthcare deals in China.

4CDH Investments (鼎晖投资)
TypeBroad incumbent
Description

Large Chinese PE/VC platform with a healthcare practice covering pharma and medical devices. Larger and more diversified than BioVenture, but competes for growth-stage Chinese healthcare deals.

TypeBroad incumbent
Description

Global healthcare-dedicated investment firm with a long-standing China presence. Competes on healthcare venture deals but operates at much larger fund sizes and global mandate.

TypeDirect peer
Description

Healthcare-dedicated venture capital firm investing across drugs, devices, and diagnostics in China. Closest direct peer given matching focus on early-to-growth Chinese healthcare with comparable AUM scale.

TypeDirect peer
Description

China's most prominent healthcare-dedicated PE/VC, investing across pharma, devices, and IVD. Direct competitor for healthcare-specific deal flow and LP capital.

TypeBroad incumbent
Description

Mega-asset manager with healthcare practice that competes across the same Chinese healthcare opportunity set, but at materially larger scale and broader portfolio mandate.

TypeDirect peer
Description

Shenzhen-headquartered Chinese VC with a meaningful healthcare practice (drugs, devices, diagnostics). Directly comparable in size, stage focus, and target deal universe.

TypeDirect peer
Description

China-focused active investor with significant healthcare allocation across biotech and innovative drugs. Competes on similar RMB-denominated healthcare venture opportunities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment199 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioVenture

Healthcare Venture Capitalbioventure.com.cn

BioVenture firmographics

Firmographics
Name
BioVenture
Legal name
苏州工业园区元生创业投资管理有限公司
Website
https://bioventure.com.cn
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

BioVenture industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Healthcare venture capital
  • Biotech investment
  • Medical device investing
  • Early-stage healthcare funding
  • Growth-stage equity investment

Where BioVenture is headquartered

Location

Headquarters

HQ city
Suzhou
HQ country
China
HQ region
Asia

Offices5 records

Markets served

BioVenture business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Management Fees: Annual management fees based on committed capital under management
  2. Carried Interest: Performance-based carried interest from successful portfolio exits and IPOs. 19 portfolio companies have listed on HKEX, STAR Board, and other exchanges.

Pricing tiers

ModelBillingPrice
OtherAnnualVC fund management and performance fees

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

BioVenture product offering

Product offering

Core offering

BioVenture (元生创投) is a China-based venture capital firm that manages RMB and USD investment funds focused exclusively on early and growth-stage healthcare companies. It deploys capital across four areas—new drug R&D, medical devices, IVD and precision medicine, and healthcare services—and supplements investment with hands-on post-investment management and value-added services through the BioBAY ecosystem.

Product overview

BioVenture (元生创投) is a healthcare-focused venture capital firm offering investment fund management services. The firm operates multiple investment funds including a RMB fund (新建元生物产业基金) and a USD Fund II, targeting early and growth-stage healthcare companies across biotech, medical devices, IVD, and healthcare services. The firm provides capital deployment, post-investment management, and value-added services to portfolio companies through its network and platform resources.

Differentiator

Problem solved

Functional benefit

Products and services

  • 新建元生物产业基金 (Xinjianyuan Bio-Industry Fund) BioVenture's first RMB fund focused on early and growth-stage life sciences investments, covering new drug R&D, medical devices, IVD, and healthcare services. The fund has a 7-year term and invests across the firm's four healthcare verticals.
  • YuanBio USD Fund II BioVenture's second USD-denominated fund investing in overseas healthcare innovation companies. Used to participate in cross-border rounds such as the Series A of BestView Laser in 2022.

Quantifiable outcome

  • 19 portfolio companies successfully listed on exchanges (HKEX, STAR Board, etc.)
  • +1 more outcomes

Companies that use BioVenture

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

BioVenture technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

BioVenture partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

BioVenture competitors and assessment

Company assessment

Direct peers

  • Qiming Venture Partners: Leading China VC with a dedicated healthcare practice spanning new drug R&D and medical devices. Comparable in stage focus (early/growth), sector, and Chinese institutional LP base.
  • Legend Capital (君联资本): Large China VC/PE firm with a substantial healthcare practice, comparable in stage and sector focus. Competes for the same growth-stage healthcare deals in China.
  • LYFE Capital: Healthcare-dedicated venture capital firm investing across drugs, devices, and diagnostics in China. Closest direct peer given matching focus on early-to-growth Chinese healthcare with comparable AUM scale.
  • Highlight Capital (高特佳投资): China's most prominent healthcare-dedicated PE/VC, investing across pharma, devices, and IVD. Direct competitor for healthcare-specific deal flow and LP capital.
  • Cowin Capital (同创伟业): Shenzhen-headquartered Chinese VC with a meaningful healthcare practice (drugs, devices, diagnostics). Directly comparable in size, stage focus, and target deal universe.
  • Loyal Valley Capital (正心谷资本): China-focused active investor with significant healthcare allocation across biotech and innovative drugs. Competes on similar RMB-denominated healthcare venture opportunities.

Broad incumbents

  • IDG Capital: Major cross-stage China VC with healthcare exposure across biotech and devices. Competes for healthcare deal flow but as part of a broader technology and consumer mandate.
  • CDH Investments (鼎晖投资): Large Chinese PE/VC platform with a healthcare practice covering pharma and medical devices. Larger and more diversified than BioVenture, but competes for growth-stage Chinese healthcare deals.
  • OrbiMed: Global healthcare-dedicated investment firm with a long-standing China presence. Competes on healthcare venture deals but operates at much larger fund sizes and global mandate.
  • Hillhouse Capital: Mega-asset manager with healthcare practice that competes across the same Chinese healthcare opportunity set, but at materially larger scale and broader portfolio mandate.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

BioVenture financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioVenture leadership team

Management profile

Number of profiles

Profiles9 records

BioVenture funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioVenture M&A and investment

M&A and investment

M&A

Investments199 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioVenture

What does BioVenture do?

BioVenture (元生创投) is a China-based venture capital firm that manages RMB and USD investment funds focused exclusively on early and growth-stage healthcare companies. It deploys capital across four areas—new drug R&D, medical devices, IVD and precision medicine, and healthcare services—and supplements investment with hands-on post-investment management and value-added services through the BioBAY ecosystem.

Is BioVenture a public or private company?

BioVenture is a private company. It is classified as management employee owned and is currently operating.

When was BioVenture founded?

BioVenture was founded in 2013. It employs 101 to 250 people.

Where is BioVenture based?

BioVenture is headquartered in Suzhou, China, in the Asia region.

How does BioVenture make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Who are BioVenture's main competitors?

Direct peers on record are Qiming Venture Partners, Legend Capital (君联资本), LYFE Capital, Highlight Capital (高特佳投资), Cowin Capital (同创伟业) and Loyal Valley Capital (正心谷资本). Broad incumbents are IDG Capital, CDH Investments (鼎晖投资), OrbiMed and Hillhouse Capital.

Does BioVenture have an API?

No public API is recorded for BioVenture.

What industry is BioVenture in?

BioVenture's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 525990 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterBeyang Therapeutics raises $30m series A for AI-designed optionsBeyang Therapeutics closed an oversubscribed series A financing of nearly $30 million, co-led by Legend Capital and Shanghai Healthcare Capital. Proceeds will fund its ExCEED design platform, preclinical and clinical studies, and overseas expansion.Fastdata极数Suzhou eye micro-innovation device developer Mingche Bio has obtained tens of millions of RMB in Series A+ financing – FastdataMingche Bio, a developer of eye micro-innovation devices, secured tens of millions of RMB in Series A+ financing led by Yuan Sheng Venture Capital. The company focuses on minimally invasive glaucoma drainage tubes and related sensor and drug delivery platforms.PrtimesCORE BiomedicineシリーズAラウンドへ参加CORE Biomedicine, a cancer drug developer, closed a Series A round of $21M (33.6 billion yen) led by East University IPC and Elikon Venture. The funding, plus AMED support, will advance IND applications and clinical development. The company targets cell lineage-based therapies beyond genomic data.FinSMEsCORE Biomedicine Raises $21M in Series A FundingCORE Biomedicine raised $21M in Series A financing co-led by UTokyo Innovation Platform and Elikon Venture. The company will use the funds to advance its lead programs through discovery and early clinical development. The firm targets core biological pathways to expand actionable patient populations.PR NewswireCORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer TherapeuticsCORE Biomedicine completed a $21 million Series A financing co-led by UTokyo Innovation Platform and Elikon Venture, plus an AMED grant. The funds will advance its lineage-based oncology therapies toward discovery and early clinical development.LeiphoneExclusive | Established for 10 months, raised 1 billion yuan, Xingyuan Intelligence increases investment in world modelsXingyuan Zhi, an embodied intelligence company, completed a new financing round, bringing its total funding to 1 billion yuan. The funds will support research on embodied brains and world models, product mass production, and team expansion. The company will establish a joint laboratory with Beijing Zhiyuan Research Institute.ChinaventureFirst release | Raised 1 billion in 10 months, the intelligence map of physical AI is coming.CRRC's Transformation and Upgrade Fund praised Xingyuan Intelligence's algorithm model for breaking traditional industrial robot limitations. The fund sees transformative potential in rail transit and new energy equipment and plans deep collaboration with Xingyuan Intelligence.PedailyXingyuan Smart has completed Pre-A round financing, with a total financing of 1 billion yuan.Beijing Xingyuan Intelligent Robot Technology Co., Ltd. completed Pre-A financing, raising 1 billion yuan in 10 months. The round was led by Songhe Capital, Chuangdongfang, and Huakong Fund, with support from state-owned enterprises. Funds will focus on embodied brain research, product production, and talent acquisition.36krXingyuanzhi completed a new round of financing-36氪Xingyuanzhi, an embodied brain company, completed a new financing round with investors including Songhe Capital, CRRC Capital, and Aiteke. The company has raised a total of RMB 1 billion. Funds will be used for R&D, mass production, and talent recruitment.36krZhipu AI: A New Unicorn Born, Raises $1 Billion in Just 10 Months After InceptionXingyuanzhi, a Beijing Academy of Artificial Intelligence-backed robotics AI firm, raised 1 billion yuan in 10 months. It develops world models that let robots predict consequences before acting. The company's solutions cover over 70% of leading embodied intelligence firms and it is the largest global shipper of NVIDIA Jetson Thor.